Durable progression-free survival benefit in early responders to elotuzumab plus lenalidomide and dexamethasone (ELd): analysis of ELOQUENT-2 4-year data in relapsed/refractory (RR) multiple myeloma (MM)

被引：0
|
作者：
Scheid, C. [1 ]
Roellig, C. [2 ]
Weisel, K. [3 ]
Salwender, H-J [4 ]
Gramatzki, M. [5 ]
Edmaier-Schroeger, K. [6 ]
Sy, O. [7 ]
Goldschmidt, H. [8 ]
机构：
[1] Univ Klinikum Koln, Cologne, Germany
[2] Univ Dresden, Dresden, Germany
[3] Univ Tubingen, Tubingen, Germany
[4] Asklepios Klin Hamburg, Hamburg, Germany
[5] Univ Schleswig Holstein, Kiel, Germany
[6] Bristol Myers Squibb, Munich, Germany
[7] Bristol Myers Squibb, Princeton, NJ USA
[8] Heidelberg Univ, Natl Ctr Tumor Dis, Heidelberg, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P571
引用
收藏
页码：189 / 189
页数：1
相关论文
共 50 条
  • [1] Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4-Year Follow-Up and Analysis of Relative Progression-Free Survival From the Randomized ELOQUENT-2 Trial
    Dimopoulos, Meletios A.
    Lonial, Sagar
    Betts, Keith A.
    Chen, Clara
    Zichlin, Miriam L.
    Brun, Alexander
    Signorovitch, James E.
    Makenbaeva, Dinara
    Mekan, Sabeen
    Sy, Oumar
    Weisel, Katja
    Richardson, Paul G.
    CANCER, 2018, 124 (20) : 4032 - 4043
  • [2] Phase 3 ELOQUENT-2 study: extended 4-year follow-up of Elotuzumab plus lenalidomide/ dexamethasone vs lenalidomide/ dexamethasone in relapsed/ refractory multiple myeloma
    Weisel, K.
    Dimopoulos, M. A.
    Lonial, S.
    White, D.
    Moreau, P.
    Mateos, M. -V.
    San Miguel, J.
    Anderson, K. C.
    Shpilberg, O.
    Grosicki, S.
    Spicka, I.
    Walter-Croneck, A.
    Magen, H.
    Belch, A.
    Reece, D. E.
    Beksac, M.
    Mekan, S.
    Sy, O.
    Singhal, A. K.
    Richardson, P. G.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 35 - 35
  • [3] PHASE 3 ELOQUENT-2 STUDY: EXTENDED 4-YEAR FOLLOW-UP OF ELOTUZUMAB PLUS LENALIDOMIDE/DEXAMETHASONE VS LENALIDOMIDE/DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Dimopoulos, M. A.
    Lonial, S.
    White, D.
    Moreau, P.
    Mateos, M. -V.
    San Miguel, J.
    Anderson, K. C.
    Shpilberg, O.
    Grosicki, S.
    Spicka, I.
    Walter-Croneck, A.
    Magen, H.
    Belch, A.
    Reece, D. E.
    Beksac, M.
    Mekan, S.
    Sy, O.
    Singhal, A. K.
    Richardson, P. G.
    Weisel, K.
    HAEMATOLOGICA, 2017, 102 : 167 - 168
  • [4] Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth
    Dimopoulos, Meletios A.
    Lonial, Sagar
    White, Darrell
    Moreau, Philippe
    Palumbo, Antonio
    San-Miguel, Jesus
    Shpilberg, Ofer
    Anderson, Kenneth
    Grosicki, Sebastian
    Spicka, Ivan
    Walter-Croneck, Adam
    Magen, Hila
    Mateos, Maria-Victoria
    Belch, Andrew
    Reece, Donna
    Beksac, Meral
    Bleickardt, Eric
    Poulart, Valerie
    Sheng, Jennifer
    Sy, Oumar
    Katz, Jessica
    Singhal, Anil
    Richardson, Paul
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 178 (06) : 896 - 905
  • [5] Elotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: Final overall survival results from the phase 3 ELOQUENT-2 trial
    Dimopoulos, Meletios A.
    Weisel, Katja
    Lonial, Sagar
    White, Darrell
    Moreau, Philippe
    Mateos, Maria-Victoria
    San-Miguel, Jesus
    Anderson, Kenneth C.
    Shpilberg, Ofer
    Grosicki, Sebastian
    Spicka, Ivan
    Walter-Croneck, Adam
    Magen, Hila
    Belch, Andrew
    Reece, Donna
    Beksac, Meral
    Ganetsky, Alex
    Jou, Ying-Ming
    McKiver, Mihaela Popa
    Singhal, Anil K.
    Richardson, Paul G.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E15 - E16
  • [6] Elotuzumab plus lenalidomide and dexamethasone (ELd) in relapsed/refractory multiple myeloma (RRMM): ELOQUENT-2 post-hoc analysis of progression-free survival (PFS), tumor regrowth by time from diagnosis and prior lines of therapy, and median duration of response (DOR)
    Weisel, K.
    Dimopoulos, M. A.
    Palumbo, A.
    Richardson, P.
    Mateos, M. -, V
    Moreau, P.
    Gupta, M.
    Sheng, J.
    Passey, C.
    Sy, O.
    Katz, J.
    Lonial, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 223 - 223
  • [7] ELOTUZUMAB IN COMBINATION WITH LENALIDOMIDE/DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (ELOQUENT-2): A 3-YEAR SAFETY UPDATE.
    Doss, Deborah
    Colson, Kathleen
    Gleason, Charise
    Richardson, Paul
    Lonial, Sagar
    ONCOLOGY NURSING FORUM, 2016, 43 (02) : 64 - 64
  • [8] Extended 5-Year Follow-Up of the Phase 3 ELOQUENT-2 Study of Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Versus Ld in Relapsed/Refractory Multiple Myeloma (RRMM)
    Lonial, Sagar
    Dimopoulos, Meletios
    Weisel, Katja
    White, Darrell
    Moreau, Philippe
    Mateos, Maria-Victoria
    San Miguel, Jesus
    Anderson, Kenneth
    Shpilberg, Ofer
    Grosicki, Sebastian
    Spicka, Ivan
    Walter-Croneck, Adam
    Magen, Hila
    Belch, Andrew
    Reece, Donna
    Beksac, Meral
    Shelat, Suresh
    Sy, Oumar
    Singhal, Anil
    Richardson, Paul
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S253 - S253
  • [9] Phase 3 ELOQUENT-2 study: Extended four year follow-up (FU) of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).
    Lonial, Sagar
    Dimopoulos, Meletios A.
    Weisel, Katja C.
    White, Darrell
    Moreau, Philippe
    Mateos, Maria-Victoria
    Miguel, Jesus San
    Anderson, Kenneth Carl
    Shpilberg, Ofer
    Grosicki, Sebastian
    Spicka, Ivan
    Walter-Croneck, Adam
    Magen, Hila
    Belch, Andrew
    Reece, Donna Ellen
    Beksac, Meral
    Mekan, Sabeen
    Sy, Oumar
    Singhal, Anil K.
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Lenalidomide and Low Dose Dexamethasone Plus Elotuzumab or Carfilzomib for Relapsed or Refractory Multiple Myeloma: A Comparison of Progression-Free Survival with Reconstructed Individual Participant Data
    Li, Shuo
    Meng, Xiang-Yu
    Maman, Souraka Tapara Dramani
    Xiao, Yong-Nong
    Li, Sheng
    BIOMED RESEARCH INTERNATIONAL, 2018, 2018
12345